Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs EXTRANEAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
Extraneal (icodextrin) is a glucose polymer that acts as an osmotic agent for peritoneal dialysis. It is absorbed from the peritoneal cavity into the bloodstream and metabolized to maltose and other oligosaccharides. Its primary mechanism is to create an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of waste products.
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
7.5% solution: 2 L intraperitoneally, dwell time 4–8 hours, up to 4 exchanges per day. For automated peritoneal dialysis: 2 L per cycle, typically 3–5 cycles overnight.
None Documented
None Documented
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
The terminal elimination half-life of icodextrin in plasma is approximately 19 hours (range 12-22 hours) following intraperitoneal administration for a dwell of 8-12 hours. This long half-life reflects slow metabolism and clearance, particularly relevant in patients with impaired renal function, leading to accumulation of maltose and other oligosaccharides.
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Icodextrin is metabolized to maltose, maltotriose, and other oligosaccharides. After intraperitoneal administration, approximately 40% of the administered dose is absorbed systemically; the absorbed icodextrin and its metabolites are primarily eliminated by renal excretion (via glomerular filtration). In patients with residual renal function, approximately 30-40% of the absorbed dose is excreted in urine over 14 days. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution